

# Special Issue

## Liver Disease and Therapy

### Message from the Guest Editor

According to the global health estimates from 2015 of the World Health Organization, around 1.2 million people worldwide die each year from liver cirrhosis and subsequent complications, while 800,000 die of hepatocellular carcinoma, comprising 3.5% of all deaths worldwide. It has also been suggested that about 296 million people around the world were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. In addition, metabolic dysfunction-associated fatty liver disease is the most common liver disease worldwide, affecting a quarter of the global population, and is often associated with adverse health outcomes. Importantly, alcohol-related liver diseases have remained as the major etiology of liver diseases in some European countries for decades. These data emphasize the importance of establishing an adequate standard of care, with the consideration of cirrhosis as a major comorbidity. Management should be focused on the prevention of the recurrence of complications, some of which now involve specific treatment. Therefore, the aim of this Special Issue is to review the current novel treatments for liver disease.

### Guest Editor

Prof. Dr. Nahum Mendez-Sanchez

1. Fundación Clínica Médica Sur, Ciudad de México, México
2. Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

### Deadline for manuscript submissions

closed (31 March 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/124047](https://mdpi.com/si/124047)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).